医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

StemExpress Announces New Distribution Partnerships

2019年04月25日 AM01:35
このエントリーをはてなブックマークに追加


 

FOLSOM, Calif.

To continue meeting the needs of clients around the world, StemExpress announces the expansion of its existing distribution network in the Asia Pacific region, adding to their current partnerships with companies in North America, Europe, and North Africa.

StemExpress now includes distribution partnerships with ATCG Limited (Hong Kong), Kim & Friends, Inc. (Korea), BIOTOOLS, Co. (Taiwan), Axil Scientific Pte Ltd (Singapore) and Custom Science (Australia).

“We play an integral role in advancing medical research on a global scale and are pleased to partner with like-minded organizations,” said Matt Phillips, vice president, marketing and sales.

Each distributor shares the same passion for timely access to high-quality biological material and shows a strong customer support system with excellent technical support and customer service ensuring topnotch client care.

The global market of regenerative medicine and cell and gene therapy is rising exponentially. Expecting to grow 35% by the year 2035, with a large area of growth occurring in Asia and Australia, StemExpress’ new partnerships will guarantee the timely supply of quality blood products to aid in the growing demands of the market to help advance medical research.

About StemExpress, LLC

Headquartered in Folsom, CA, StemExpress is the leading global Biospecimen provider of human primary cells and blood products. StemExpress has a reliable and streamlined process starting with donor recruitment to shipping the final product guaranteeing every sample has the highest purity, viability, and quality.

For more information, please visit https://www.stemexpress.com/distributors/ or call 530-303-3828.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190424005865/en/

CONTACT

Katherine Elorduy
Cell: 916-217-9727
kelorduy@stemexpress.com

同じカテゴリーの記事 

  • Todd Clegg 担任 Carestream 首席执行官
  • Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release
  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权